Abstract
It is imperative to maintain normal blood flow to provide adequate oxygen supply to specific organs and cells, as well as for the removal of metabolic byproducts. Therefore, any situation that results in blood clotting can injure or kill living tissues. In this paper, we describe a case where a protein C deficient subject who would, by all medical indicators, be at 100 % risk of experiencing thrombophlebitis, deep vein thrombosis, and or lung emboli, is able to escape all pathologies by using perioperative zymogen protein C (ZPC). This protein C deficient patient has a long history of blood clotting, particularly from surgical procedures. The patient is 81 years old and first experienced clotting due to hernia surgery in 1964, when he was hospitalized for 16 days post-surgery with life threatening complications. It was later determined in 1980, after many episodes, that the patient had hereditary protein C deficiency at the 38 % level. In his hernia surgery, perioperative ZPC was used along with accepted anticoagulation procedures with no blood clots or other related side effects occurring. This procedure can greatly benefit protein C deficient patients, and could potentially find use for non-PC deficient patients in surgeries and a variety of other medical treatments. This particular case helps to validate the importance of ZPC in effecting safer surgery in high-risk patients. It also supports the mechanism of ZPC acting as an anticoagulant without causing bleeding. Most importantly, each clinical case study represents a unique combination of surgeon, hematologist, medical staff, and patient functioning as a coordinated team. In this case, smaller amounts of very expensive ZPC achieved safe and efficacious results, which is hugely important for future clinical applications when considering the production cost of ZPC. More studies must be done to establish minimum dosing while achieving safe and efficacious outcomes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
National Blood Clot Alliance (n.d.) Blood clot statistics vary – what to do about it? NBCA Stop the Clot News. Web. 23 May 2014
Bicher HI, Bruley DF, Knisely MH (1973) Anti-adhesive drugs and tissue oxygenation. In: Bruley DF, Bicher HI (eds) Oxygen transport to tissue, vol 37, Advances in experimental medicine and biology. Plenum Press, New York
Esmon CT (1989) The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264(9):4743–4746
Goro FW (1948) Blood sludge. Life Mag 24(22):49–59
Walker FJ, Sexton PW, Esmon CT (1979) The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochim Biophys Acta 571(2):333–342
Bertina RM (1988) Protein C and related proteins: biochemical and clinical aspects, Contemporary issues in haemostasis and thrombosis. Churchill Livingstone, New York
Stenflo J (1976) A new vitamin K-dependent protein. J Biol Chem 251:355–363
Sharma GR, Grinnell BW et al (2008) Activated protein C modulates chemokine response and tissue injury in experimental sepsis. In: Kang KA, Harrison DK, Bruley DF (eds) Oxygen transport to tissue XXIX, vol 614, Advances in experimental medicine and biology. Springer, New York, pp 83–91
Esmon CT (1990) Regulation of coagulation: the nature of the problem. In: Bruley DF, William N (eds) Drohan protein C and related anticoagulants, vol 2, Advances in applied biotechnology series. Gulf Publishing Company, Houston, p 3
Bruley DF, Drohan WN (1990) Protein C and related anticoagulants, vol 11, Advances in applied biotechnology series. Gulf Publishing Company, Houston
Bruley DF (2009) Zymogen protein C concentrate for safer heterozygote surgery, I am a guinea pig! In: Liss P, Hansell P, Bruley DF (eds) Oxygen transport to tissue XXX, vol 645, Advances in experimental medicine and biology. Springer Publishing, New York, pp 115–21
Bruley DF, Mears SC, Streiff MB (2010) Safer surgery using zymogen protein C concentrate. In: Takahashi EJ, Bruley DF (eds) Oxygen transport to tissue XXXI, vol 662, Advances in experimental medicine and biology. Springer Publishing, New York, pp 439–45
Bruley DF, Jagannath SB, Streiff MB (2011) Zymogen protein C to prevent clotting without bleeding during invasive medical procedures. In: LaManna JC et al (eds) Oxygen transport to tissue XXXII, vol 701, Advances in experimental medicine and biology. Springer Publishing, New York, pp 91–7
Thakkar SC, Streiff MB, Bruley DF et al (2010) Perioperative use of protein c concentrate for protein c deficiency in THA. Clin Orthop Relat Res 468(7):1986–1990
Bruley DF, Streiff MB (2013) Nature’s “silver bullet” for anticoagulation: mechanism of zymogen protein C to activated protein C. In: Wolf M, Bucher HU, Rudin M, Van Huffel S, Wolf U, Bruley DF, Harrison DK (eds) Oxygen transport to tissue XXXIII, vol 765, Advances in experimental medicine and biology. Springer Publishing, New York, pp 15–21
Bruley DF, Schulick RD, Streiff MB (2013) Pancreaticoduodenectomy using perioperative zymogen protein C to help prevent blood clotting: a trilogy on increased patient safety. In: Van Huffel S, Naulaers G, Caicedo A, Bruley DF, Harrison DK (eds) Oxygen transport to tissue XXXV, vol 789, Advances in experimental medicine and biology. Springer Publishing, New York, pp 299–307
Marlar RA, Montgomery RR, Broakman AW (1989) Diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis. J Pediatr 114(4 Pt 1):528–534
Mahmoodi BK, Brouwer JL, Veeger NJ et al (2008) Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 118:1659–1667
Gatti L, Carnelli V, Rusconi R et al (2003) Heparin-induced thrmobocytopenia and warfarin-induced skin necrosis in a child with severe protein C deficiency: successful treatment with dermatan sulfate and protein C concentrate. J Thromb Haemost 1:387–388
Knoebl PN (2008) Human protein C concentrates for replacement therapy in congenital and acquired protein C deficiency. Drugs Today (Barc) 44:429–441
Schellongowski P, Bauer E, Holzinger U et al (2006) Treatment of adult patients with sepsis-induced coagulopathy and purpura fulminans using a plasma-derived protein C concentrate (Ceprotin). Vox Sang 90:294–301
White B, Livingstone W, Murphy C et al (2000) An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 96:3719–3724
Toupance O, Nguyen P, Brandt B et al (1994) Prevention of vascular thrombosis by human purified protein C concentrate in a patient with familial PC deficiency undergoing renal transplantation. Transpl Int 7:144–145
Wu H, Bruley DF (1999) Homologous blood protein separation using immobilized metal affinity chromatography: protein C separation from prothrombin with application to the separation of facto IX and prothrombin. Biotechnol Prog 15(5):928–931
Wu H, Bruley DF (2002) Chelator, metal ion and buffer studies for protein c separation. Comp Biochem Physiol A Mol Integr Physiol 132(1):213–220
Thiessen EE, Bruley DF (2003) Theoretical studies of IMAC interfacial phenomena for the purification of protein C. In: Thorniley MS, James PE (eds) Oxygen transport to tissue XXV, vol 540, Advances in experimental medicine and biology. Springer, New York, p 183
Porath J (1992) Immobilized metal ion affinity chromatography. Protein Expr Purif 3(4):263–281
Korah LK, Ahn DG, Kang KA (2003) Mini-antibody production process for the purification of protein C. In: Wilson DF, Evans SM, Biaglow J, Pastuszko A (eds) Oxygen transport to tissue XXIII, vol 510. Kluwer Academic/Plenum Publishers, New York, pp 127–132
Velander WH, Lubon H, Drohan WN (1997) Transgenic livestock as drug factories. Sci Am 276(1):70–74
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this paper
Cite this paper
Bruley, D.F. et al. (2016). A Compelling Case for the Use of Perioperative Zymogen Protein C for Increased Patient Safety. In: Luo, Q., Li, L., Harrison, D., Shi, H., Bruley, D. (eds) Oxygen Transport to Tissue XXXVIII. Advances in Experimental Medicine and Biology, vol 923. Springer, Cham. https://doi.org/10.1007/978-3-319-38810-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-38810-6_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-38808-3
Online ISBN: 978-3-319-38810-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)